Earlier this year, the biotech company featured in today’s article was a penny stock. But after uplisting to the Nasdaq, the author of today’s article notes that “it has been making big moves in the market and moving some of Wall Street’s top analysts to set initial targets over $20 right now.” For more on how this company’s approach to…
“In a world where interest rates are so low and uncertainty seems to be the norm, baby boomers need to look for stable dividend stocks that can compete with the current income of longer-term Treasury notes “Favorable government regulations, coupled with the introduction of new and sophisticated products, and growing demand for synthetic biology, should keep driving the biotech industry’s…
The author of today’s article advises that “before investing in a biotech company, it’s essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.” With that, they proceed to highlight two biotech stocks that could be top picks right now based on the great…
“Some of the market’s most rewarding opportunities can be found in small-cap stocks,” declares the author of today’s article – and with that, he proceeds to highlight three of the most popular small-cap stocks right now among Robinhood investors. For these three stocks – which include a veterinary health company with a medical device that could help it tap into…
The author of today’s article’s favorite healthcare stock right now is a tech stock for the healthcare industry whose software is helping revolutionize the drug discovery process. More specifically, its solution “helps big pharma find the right molecule for the right target, and it helps them do it a lot quicker than normal human research” – and it’s being used…
The clinical-stage biotech featured in today’s article, focused on developing treatments for fibrosis, cancer and other related diseases, has gained 18.7% over the past month. In order to determine whether it can continue its ascension and become a winner in the biotech industry, the author takes a look at the factors that could influence its performance in the coming months.…
Strong and sustained share price appreciation, solid upside potential, an outlook toward further growth, and approval from Wall Street analysts characterize the three “monster growth stocks” highlighted in today’s article – all of which are hovering at or near one-year highs and have the potential to reach new highs. For these three stocks – including a developmental-stage biopharmaceutical company focused…
Of the biotech industry, the author of today’s article notes that it “has seen its share of losses over the past couple of months but that provides us the perfect opportunity to pick up shares of stocks that could see substantial gains in the months ahead.” With that, he proceeds to highlight three undervalued biotech stocks poised to see their…
A rumored takeover candidate is among the five small-cap biotech stocks trading under $10 highlighted in today’s article, all of which boast Buy ratings from well-known Wall Street firms – and solid upside potential. For these five biotech stocks, which are suited for very aggressive investors, CLICK HERE.
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s article of the five stocks he highlights – all of which have Buy ratings at major firms and are trading under the $10 level. For these five stocks –which include an intriguing biotech play with…